Photo by moino007 from unsplash
This cohort study assesses the association of upfront peptide receptor radionuclide therapy (PRRT) vs upfront chemotherapy or targeted therapy with progression-free survival among patients in Italy with enteropancreatic neuroendocrine tumors… Click to show full abstract
This cohort study assesses the association of upfront peptide receptor radionuclide therapy (PRRT) vs upfront chemotherapy or targeted therapy with progression-free survival among patients in Italy with enteropancreatic neuroendocrine tumors who experienced disease progression after treatment with somatostatin analogues.
Keywords:
receptor radionuclide;
association upfront;
progression;
peptide receptor;
radionuclide therapy;
upfront peptide
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!